Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Cassava Sciences, Inc. which may affect shareholder rights [1] Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of Cassava may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and enhancing shareholder value through better oversight [3] Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - WhiteFiber, Inc. (WYFI) is up 21% at $17.35 [3] - Rising Dragon Acquisition Corp. (RDAC) is up 21% at $12.63 [3] - Julong Holding Limited (JLHL) is up 13% at $3.45 [3] - Linkhome Holdings Inc. (LHAI) is up 11% at $12.50 [3] - A SPAC III Acquisition Corp. (ASPC) is up 9% at $13.09 [3] - Intuitive Machines, Inc. (LUNR) is up 7% at $11.61 [3] - Ascent Solar Technologies, Inc. (ASTI) is up 7% at $3.31 [3] - Bitmine Immersion Technologies, Inc. (BMNR) is up 6% at $30.39 [3] - Velo3D, Inc. (VELO) is up 5% at $12.10 [3] - Gain Therapeutics, Inc. (GANX) is up 4% at $2.36 [3] Premarket Losers - cbdMD, Inc. (YCBD) is down 17% at $1.60 [4] - Mega Fortune Company Limited (MGRT) is down 16% at $7.33 [4] - Cassava Sciences, Inc. (SAVA) is down 14% at $2.43 [4] - NIKE, Inc. (NKE) is down 10% at $59.01 [4] - InMed Pharmaceuticals Inc. (INM) is down 6% at $1.21 [4] - Datacentrex, Inc. (DTCX) is down 5% at $3.23 [4] - Abundia Global Impact Group Inc (AGIG) is down 5% at $1.50 [4] - PSQ Holdings, Inc. (PSQH) is down 5% at $1.00 [4] - Paranovus Entertainment Technology Ltd. (PAVS) is down 4% at $2.34 [4] - Worksport Ltd. (WKSP) is down 4% at $2.09 [4]

Core Insights - After-hours trading on Thursday was relatively quiet, with small-cap biotech stocks showing modest movements [1] Company Summaries - **Delcath Systems, Inc. (DCTH)**: The stock rose to $8.52, up 4.02% or $0.33 after announcing a $25 million share repurchase program, reflecting confidence in its long-term outlook [2] - **BioVie Inc. (BIVI)**: The stock climbed to $1.44, a gain of 13.39% or $0.17, despite no specific news, indicating speculative or technical-driven activity [3] - **Cassava Sciences, Inc. (SAVA)**: The stock advanced to $2.87, up 9.17% or $0.24, following a narrower net loss of $10.8 million reported in Q3, compared to $27.9 million a year earlier, with $106.1 million in cash and no debt [4] - **Enlivex Therapeutics Ltd. (ENLV)**: The stock edged higher to $0.95, up 4.24% or $0.04, with no company-specific news released [5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Super League Enterprise, Inc. (SLE) increased by 170% to $8.86 [3] - Galecto, Inc. (GLTO) rose by 93% to $5.80 [3] - STRATA Skin Sciences, Inc. (SSKN) saw an 85% increase to $3.15 [3] - Professional Diversity Network, Inc. (IPDN) gained 69% reaching $4.85 [3] - Soluna Holdings, Inc. (SLNH) was up 33% at $2.81 [3] - Better Home & Finance Holding Company (BETR) increased by 29% to $64.80 [3] - MicroCloud Hologram Inc. (HOLO) rose by 23% to $6.87 [3] - Cassava Sciences, Inc. (SAVA) increased by 17% to $2.73 [3] - Werewolf Therapeutics, Inc. (HOWL) saw a 12% rise to $2.06 [3] - Skyline Builders Group Holding Limited (SKBL) was up 9% at $3.67 [3] Premarket Losers - Psyence Biomedical Ltd. (PBM) decreased by 18% to $3.70 [4] - Diginex Limited (DGNX) fell by 16% to $14.78 [4] - Qualigen Therapeutics, Inc. (QLGN) dropped 17% to $4.58 [4] - Boxlight Corporation (BOXL) saw a 17% decline to $3.94 [4] - AgriFORCE Growing Systems Ltd. (AGRI) decreased by 15% to $4.86 [4] - Firefly Aerospace Inc. (FLY) fell by 10% to $44.50 [4] - ARB IOT Group Limited (ARBB) decreased by 10% to $9.11 [4] - Sharps Technology, Inc. (STSS) saw an 8% decline to $7.24 [4] - CAMP4 THERAPEUTICS CORPORATION (CAMP) dropped by 6% to $2.58 [4] - Bollinger Innovations, Inc. (BINI) decreased by 5% to $8.00 [4]

Group 1: Kenvue and Acetaminophen Controversy - Kenvue's stock rebounded by 6% in premarket trading after a 7.5% drop due to concerns raised by the Trump administration regarding acetaminophen use during pregnancy [3][4]. - The company, a spinoff of Johnson & Johnson, defends acetaminophen as the safest pain reliever for pregnant women, citing rigorous research and endorsements from medical professionals [5]. - The FDA has issued a strong recommendation against the use of acetaminophen during pregnancy, which may lead to potential lawsuits for Kenvue [6]. Group 2: Boeing's Major Order - Boeing received an order from Uzbekistan Airways for up to 22 787 Dreamliner jets, marking the airline's largest-ever purchase [7]. - The order includes 14 787-9 airplanes with options for eight additional jets, aimed at modernizing Uzbekistan Airways' fleet and expanding international routes [8]. Group 3: Meta's New Dating Features - Meta Platforms introduced new features in its Facebook Dating service to combat "swipe fatigue," including a dating assistant chatbot and a "Meet Cute" feature for surprise matches [10][11]. - The introduction of these features negatively impacted shares of rival dating services, with Match Group and Bumble seeing declines of 5.4% and 3% respectively [12].

Group 1: Super League Enterprise, Inc. - Super League Enterprise, Inc. announced a $10 million strategic equity investment from Evo Fund, leading to a sharp increase in its stock price [1] - Shares of Super League Enterprise rose 200% to $9.83 in pre-market trading following the announcement [1] Group 2: Other Notable Gainers - Professional Diversity Network, Inc. gained 88.8% to $5.40 in pre-market trading after a previous rise of around 4% [4] - STRATA Skin Sciences, Inc. rose 80% to $3.06 in pre-market trading after an 8% increase on Monday [4] - Jiuzi Holdings, Inc. jumped 50.9% to $1.69 in pre-market trading after a 5% gain on Monday [4] - New Era Energy & Digital, Inc. gained 47.2% to $0.8941 in pre-market trading after a surge of around 12% on Monday [4] - Better Home & Finance Holding Company increased by 30% to $64.95 in pre-market trading, following a 46% jump on Monday [4] - MicroCloud Hologram Inc. surged 29% to $7.17 in pre-market trading after announcing a breakthrough in quantum technology [4] - Cassava Sciences, Inc. rose 24.1% to $2.88 in pre-market trading after CEO Richard Barry purchased shares at an average price of $2.25 [4] - SES AI Corporation surged 10.3% to $2.04 in pre-market trading after a 17% increase on Monday [4] - Ballard Power Systems Inc. gained 8.3% to $3.12 in pre-market trading after a 5% rise on Monday [4] Group 3: Notable Decliners - Psyence Biomedical Ltd. dipped 19.6% to $3.65 in pre-market trading after a decline of around 5% on Monday [4] - Diginex Limited shares fell 17.7% to $14.60 in pre-market trading after a jump of over 30% on Monday [4] - Addentax Group Corp. declined 16.5% to $0.9021 in pre-market trading after gaining more than 30% on Monday [4] - Boxlight Corporation fell 15.5% to $4.03 in pre-market trading after a significant jump of 205% on Monday [4] - Reliance Global Group, Inc. dropped 15.5% to $0.9122 in pre-market trading after a 47% increase on Monday [4] - Qualigen Therapeutics, Inc. declined 14.1% to $4.75 in pre-market trading after a 95% jump on Monday [4] - Fly-E Group, Inc. fell 13.1% to $0.8773 in pre-market trading after announcing a securities purchase agreement [4] - Firefly Aerospace Inc. dropped 12.5% to $43.29 in pre-market trading after reporting a second-quarter loss [4] - Opendoor Technologies Inc. dipped 6.3% to $7.85 in pre-market trading after a 12% fall on Monday [4] - Symbotic Inc. fell 4.8% to $57.80 in pre-market trading after a gain of more than 6% on Monday [4]

Core Insights - Several biotech companies experienced significant stock price increases in after-hours trading, driven by clinical updates, strategic shifts, and upcoming catalysts [1] Cassava Sciences (SAVA) - Shares surged 37.1% to $3.18 in after-hours trading, following a regular session close of $2.32, which marked a 1.75% gain [2] - The rally is attributed to renewed interest in the investigational drug simufilam, particularly its potential in treating TSC-related epilepsy, following positive preclinical data [3] - Leadership changes, including the appointment of Dr. Joseph Hulihan as Chief Medical Officer, indicate a strategic pivot in clinical priorities [3] - Future updates on simufilam and the diagnostic candidate SavaDx could serve as near-term catalysts [4] Helius Medical Technologies (HSDT) - Stock rose 15.67% to $18.53 in after-hours trading after a regular session close of $16.02, where it had dropped 33.61% [4] - The rebound followed a $500 million private placement announcement, marking a significant pivot from its core neurotech focus [5] - Helius continues to advance its medical device pipeline, with positive results from the Portable Neuromodulation Stimulator (PoNS) stroke registrational program and plans for FDA submission [6] Werewolf Therapeutics (HOWL) - Shares increased 9.78% to $2.02 in after-hours trading, following a regular session close of $1.84, which was up 23.49% [6] - The company is advancing multiple conditionally activated cytokine therapies through its INDUKINE platform, with lead candidate WTX-124 in a Phase 1/1b trial targeting advanced solid tumors [7] - Participation in the H.C. Wainwright 27th Annual Global Investment Conference highlighted management's timelines for clinical readouts and pipeline progress [8] Aytu BioPharma Inc. (AYTU) - Stock rose 7.63% to $2.68 in after-hours trading after closing at $2.49, up 2.05% [8] - The price action follows the announcement of full-year and Q4 fiscal 2025 results expected on September 23, 2025, which will clarify commercial performance and progress with EXXUA [9] - Aytu maintains a portfolio of pediatric and ADHD-focused therapeutics and has extended its loan agreement with Eclipse to boost liquidity [10] Equillium Inc. (EQ) - Shares increased 10.34% to $1.60 in after-hours trading after closing at $1.45, down 0.68% [10] - The company announced up to $50 million in financing to advance EQ504 into clinical development, with positive feedback from the FDA regarding its regulatory pathway [11] - Its lead candidate, itolizumab (EQ001), is in Phase 3 trials for acute graft-versus-host disease and has completed earlier-stage studies in lupus nephritis and ulcerative colitis [11]

Core Viewpoint - Cassava Sciences, Inc. announces the retirement of Chief Medical Officer James W. Kupiec, MD, effective May 9, 2025, and the appointment of Jack Moore, PhD, as Senior Vice President of Clinical Development, effective April 28, 2025, to advance the clinical evaluation of simufilam for CNS disorders, including TSC-related epilepsy [1][3][8] Company Leadership Changes - James W. Kupiec, MD, retires after a notable career in Alzheimer's disease drug development, contributing to high-quality clinical trials at Cassava [2] - Jack Moore, PhD, brings extensive experience in CNS drug development and will focus on advancing simufilam in new indications [3][4] Clinical Development Focus - Dr. Moore will be responsible for the clinical evaluation of simufilam, targeting TSC-related epilepsy and exploring additional applications [3][5] - The company aims to identify potential clinical collaborators and study sites as part of its strategy for the TSC program [4] Background of Jack Moore - Jack Moore has a strong background in biopharmaceuticals, with experience in CNS and neurodegenerative diseases, having held leadership roles at major pharmaceutical companies [6] - He holds a PhD in Neuroscience and has a history of engaging with key opinion leaders and patient advocacy groups [7] Company Overview - Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing investigational treatments for CNS disorders, including simufilam, which targets the filamin A protein [8]

Core Viewpoint - Cassava Sciences, Inc. (SAVA) has experienced a significant downtrend, with a 39.5% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - SAVA's current RSI reading is 24.25, indicating that the heavy selling pressure may be exhausting, which could lead to a price rebound [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding SAVA's earnings potential, with a reported 11.3% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term, supporting the case for a potential turnaround for SAVA [7]. Group 3: Analyst Ratings - SAVA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a near-term turnaround [8].

Company Overview - Cassava Sciences (SAVA) recently faced a significant setback as its phase III study REFOCUS-ALZ for simufilam in mild-to-moderate Alzheimer's disease failed to meet the prespecified co-primary endpoints [1][4] - The study enrolled 1,125 Alzheimer's disease patients who received either simufilam or placebo for 76 weeks, but the drug did not show a significant reduction in cognitive and functional decline compared to placebo [2][3] Study Results - Treatment with simufilam did not achieve significant results on the ADAS-COG12 and ADCS-ADL scales over the 76-week period, nor did it meet any secondary or exploratory biomarker endpoints [2] - Despite the lack of efficacy, simufilam maintained an acceptable safety profile throughout the study [3][4] Program Termination - Following the failure of the REFOCUS-ALZ study, Cassava decided to discontinue the study and will phase out the development of simufilam for Alzheimer's disease by the end of the second quarter [4] - With the termination of this program, Cassava no longer has any late-stage candidates in its pipeline [4] Financial Position - As of December 2024, Cassava reported having $128.6 million in cash and equivalents, raising concerns about its ability to fund future operations [5] Industry Context - The Alzheimer's disease market is characterized by significant challenges in drug development, with many pharmaceutical and biotech companies experiencing setbacks [6] - Currently, there are two FDA-approved drugs for Alzheimer's disease: Leqembi and Kisunla, which target the reduction of amyloid beta plaques in the brain [7][8]